



**JOHN WAYNE  
CANCER INSTITUTE**  
at Providence Saint John's Health Center

For more information, contact  
the Neuro-Oncology  
Clinical Trial Team at:  
neuro.oncology@jwci.org  
310-829-8265

**Clinical Trial Investigators**

Achal S. Achrol, MD

Garni Barkhoudarian, MD

Daniel Kelly, MD

Santosh Kesari, MD, PhD

Steven O'Day, MD

Marlon Garzo Saria, PhD, RN

**Clinical Trial Team**

Najee Boucher, CRA  
najee.boucher@providence.org  
310-582-7460

Jaya Gill, RN, BSN  
jaya.gill@providence.org  
310-582-7437

Annie Heng, RN, BSN  
HengA@jwci.org  
310-582-7457

Tiffany Juarez, PhD  
Tiffany.Juarez@jwci.org  
310-449-5225

Anand Moses, CRA  
MosesA@jwci.org  
310-582-7097

**Sponsor**

PNI/JWCI & BIPI

**Saint John's  
Health Center**



# CLINICAL TRIAL ANNOUNCEMENT

## A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer

This study is a Phase I dose escalation and CNS pharmacokinetic study of the ErbB family inhibitor **afatinib** in patients with recurrent or progressive brain cancer. It is an open-label, single institution, 3+3 dose escalation study to describe the safety and tolerability of afatinib in patients with brain cancer having failed prior therapy and to determine the recommended phase II dose.

Eligible patients will receive **afatinib** in treatment cycles of 28 days that will consist of **afatinib** administered orally by mouth once every four days. Patients will be assigned to the dose level open at the time of their enrollment. Patients will continue dosing of **afatinib** until disease progression, unacceptable toxicity, withdrawal of consent, or treating physician determines it is in their best interest to stop.

**Afatinib** (BIBW2992; Gilotrif®) is a small molecule, selective and irreversible ErbB family blocker. In preclinical models it effectively inhibits EGFR, HER2 and HER4 phosphorylation resulting in tumour growth inhibition and regression of established subcutaneous tumours derived from four human cell-lines known to co-express ErbB receptors.

### Key Inclusion Criteria:

- Histologically confirmed diagnosis of central nervous system cancer of any kind including: glioblastoma (GBM), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed oligoastrocytoma (AMO), low grade gliomas, brain metastases, meningiomas, leptomeningeal metastases, chordomas, pituitary tumors, medulloblastomas
- Failed prior standard therapy
- Age  $\geq$  18 years
- Karnofsky Performance Status  $\geq$  60%

### Exclusion Criteria:

- Insufficient time from prior therapy to study entry
- Current or anticipated use of enzyme-inducing anti-epileptic drugs
- Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study

Please feel free to contact the clinical trial team to learn more about this study.